FDA OK's Impavido in leishmaniasis; Knight wins priority voucher

The FDA late on 19 March granted approval to Knight Therapeutics to market Impavido (miltefosine) as a treatment for cutaneous, mucosal and visceral leishmaniasis, a parasitic disease transmitted by the phlebotomine sand flies and is found in parts of the tropics, subtropics and southern Europe.